| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0027 | 1 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.0016 | 1 |